姑息性EUS引导胆道引流采用腔壁贴合金属支架的前瞻性多中心可行性研究
本研究为英国3家三级中心的前瞻性多中心研究,纳入20例因不可手术恶性远端胆总管狭窄且ERCP胆道引流失败、胆总管扩张≥14 mm的成人患者,评估EUS引导胆道引流(EUS-BD)使用腔壁贴合金属支架的技术可行性、安全性和生活质量。
要点
- EUS-BD使用腔壁贴合金属支架在ERCP失败的恶性远端胆总管狭窄患者中技术成功率高。
- 第7天临床成功率达95%,第30天为92.3%,生活质量评分显著改善。
- 30天全因死亡率20%,中度不良事件率10%,包括胆管炎和支架移位各1例。
核心结论
- EUS-BD作为不可手术恶性远端胆总管狭窄的二线姑息治疗,具有可接受的技术成功率和安全性。
- 需要随机对照研究比较EUS-BD与经皮肝穿刺胆道引流以确定其临床实践中的有效性。
研究设计与样本
- 前瞻性多中心可行性研究,从英国3家三级中心筛选并招募连续成人患者。
- 纳入标准为因不可手术恶性远端胆总管狭窄导致胆总管扩张≥14 mm且ERCP胆道引流失败。
- 共纳入20例患者进行分析。
- 主要终点为使用腔壁贴合金属支架的EUS-BD技术成功。
- 次要终点包括血清胆红素水平改善、30天死亡率、操作相关不良事件和生活质量(EORTC QLQ-BIL21问卷)。
主要发现
- EUS-BD在所有患者中技术成功。
- 第7天临床成功率为95%(19/20),定义为胆红素水平下降>50%。
- 第30天临床成功率为92.3%(12/13),定义为胆红素<50 μmol/L。
- 第30天整体生活质量评分显著改善(49 vs 42,P = .03)。
- 30天全因死亡率为20%,中度不良事件率为10%(1例胆管炎和1例支架移位)。
关键数值与推荐
- 纳入患者胆总管扩张≥14 mm。
- 第7天临床成功定义为胆红素水平下降>50%。
- 第30天临床成功定义为胆红素<50 μmol/L。
- 生活质量评分第30天为49 vs 42,P = .03。
- 30天全因死亡率20%,中度不良事件率10%。
临床怎么用
- 对于ERCP引流失败的不可手术恶性远端胆总管狭窄患者,可考虑EUS-BD使用腔壁贴合金属支架作为二线姑息治疗。
- 需关注操作相关不良事件如胆管炎和支架移位,并监测30天死亡率。
局限性
- 样本量较小(20例),为可行性研究。
- 缺乏与经皮肝穿刺胆道引流的随机对照比较。
- 需要随机对照研究进一步确定其有效性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Biliary drainage with ERCP is successful in only 80% to 90% of cases of extrahepatic cholangiocarcinoma and pancreatic cancer. We present the results of a multicenter prospective study assessing the safety, feasibility, and quality of life of patients after EUS-guided biliary drainage (EUS-BD) with lumen-apposing metal stents after failed ERCP. METHODS: All consecutive adults with a dilated common bile duct (CBD) ≥14 mm secondary to inoperable malignant distal CBD stricture and failed ERCP biliary drainage were screened and recruited from 3 tertiary UK centers. Technical success of EUS-BD using lumen-apposing metal stents was the primary endpoint. Improvement in serum bilirubin level, 30-day mortality, procedure-related adverse events, and quality of life were secondary endpoints. Improvement in quality of life was measured using a validated questionnaire (EORTC QLQ-BIL21). RESULTS: Twenty patients were included in the analysis. EUS-BD was technically successful in all patients and the clinical success rate was 95% (19 of 20) at day 7 (>50% reduction in bilirubin level) and 92.3% (12 of 13) at day 30 (bilirubin <50 μmol/L). There were significant improvements in overall quality of life score (49 vs 42, P = .03) at day 30. All-cause 30-day mortality was 20% and the moderate adverse event rate was 10% (1 cholangitis and 1 stent migration). CONCLUSION: EUS-BD has acceptable technical success and safety as a second-line palliative treatment for inoperable malignant distal CBD strictures. Randomized controlled studies comparing EUS-BD with percutaneous transhepatic biliary drainage are needed to determine their effectiveness in clinical practice. (ISCRTN registration number: ISRCTN13196704.).
引用
- Venkatachalapathy SV, James MW, Huggett MT, et al. Utility of palliative EUS-guided biliary drainage using lumen-apposing metal stents: a prospective multicenter feasibility study (with video). Gastrointest Endosc. 2021. PMID: 33545136. doi:10.1016/j.gie.2021.01.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。